Integrating theories of proactive motivation, team innovation climate, and motivation in teams, we developed and tested a multilevel model of motivators of innovative performance in teams. Analyses of multisource data from 428 members of 95 research and development (R&D) teams across 33 Chinese firms indicated that team-level support for innovation climate captured motivational mechanisms that mediated between transformational leadership and team innovative performance, whereas members' motivational states (role-breadth self-efficacy and intrinsic motivation) mediated between proactive personality and individual innovative performance. Furthermore, individual motivational states and team support for innovation climate uniquely promoted individual innovative performance, and, in turn, individual innovative performance linked team support for innovation climate to team innovative performance.

A pH and thermo dual-controllable composite structure was developed as a triggerable drug delivery carrier. In such a drug carrier, a mesoporous silica nanoparticle (MSN) acts as the drug loading core, while a layer of copolymer-lipid serves as the dual-responsive gating shell. Specifically, the copolymer-lipid bilayer consists of natural phospholipids (soy phosphatidylcholine, SPC) and the poly(N-isopropylacrylamide-methacrylic acid-octadecyl acrylate) (p(NIPAM-MAA-ODA)) copolymer. With this structure, a high drug loading capacity and a sustained release effect could be provided by the MSN core, while a pH and thermo dual-responsive releasing ability could be offered by the copolymer-lipid bilayer. In addition, the introduction of SPC instead of the traditionally used phospholipids (such as dioleoyl phosphatidylethanolamine (DOPE) or dipalmitoyl phosphatidylcholine (DPPC)) results in a much lower cost and a better serum stability. Using doxorubicin (DOX) as the drug model, our results confirmed that either pH or temperature can trigger the drug release. However, much more drugs could be released by simultaneously controlling the pH and temperature. Furthermore, after being cocultured with cancer cells (MCF-7), the drug carriers transported DOX into the cells and exhibited a pH-sensitive release behavior. Since most tumor sites usually exhibit a more acidic environment or a higher temperature, the pH- and thermo-responsive releasing ability of this drug carrier is particularly useful and important for the targeted release at the tumor region. Thus, due to the powerful controlled releasing ability, the straightforward preparation method, and low cost, the demonstrated nanocarrier will have potential applications in controllable drug delivery and cancer therapy.

Metal–organic framework (MOF) has been extensively explored in a number of fields due to its diverse properties. In this work, we demonstrated the potential of MOF in the establishment of a self-assembled fluorescence resonance energy transfer (FRET) system for developing ratiometric fluorescent nanoprobe. For this purpose, zeolitic imidazolate framework-8 (ZIF-8) was selected as a MOF model to entrap carbon dot (CD) and curcumin (CCM) during its self-assembly, which produces CD/CCM@ZIF-8. Benefiting from the confinement effect of ZIF-8, the loaded CD and CCM can be brought in close proximity for energy transfer to occur. Under optimal conditions, a high FRET efficiency of 68.7% can be obtained. Importantly, compared with traditional FRET systems, the fabrication process of CD/CCM@ZIF-8 is much more simple and straightforward, which does not involve the elaborate design and complicated synthesis of molecular linkers. However, in the presence of hypochlorous acid (HClO), the FRET process from CD to CCM will be disrupted, rendering CD/CCM@ZIF-8 to display a ratiometric response to HClO. This finding led to a method for ratiometric fluorescent detection of HClO with a detection limit of 67 nM and excellent selectivity over other reactive oxygen species. We believe that this study can give a new insight into the rational design and application of FRET-based nanoprobes.

Triptolide, an abietane-type diterpenoid isolated from Tripterygium wilfordii Hook. F., has significant pharmacological activity. Research results show that triptolide has obvious inhibitory effects on many solid tumors. Therefore, triptolide has become one of the lead compounds candidates for being the next "blockbuster" drug, and multiple triptolide derivatives have entered clinical research. An increasing number of researchers have developed triptolide synthesis methods to meet the clinical need. To provide new ideas for researchers in different disciplines and connect different disciplines with researchers aiming to solve scientific problems more efficiently, this article reviews the research progress made with analyzes of triptolide pharmacological activity, biosynthetic pathways, and chemical synthesis pathways and reported in toxicological and clinical studies of derivatives over the past 20 years, which have laid the foundation for subsequent researchers to study triptolide in many ways.

No abstract